Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation



Status:Completed
Conditions:Atrial Fibrillation
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:19 - Any
Updated:5/5/2014
Start Date:August 2008
End Date:June 2013
Contact:Kyle Ulveling, MD
Phone:402-280-4566

Use our guide to learn which trials are right for you!

Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm

This study aims to evaluate the utility of the atrial electromechanical interval and pulse
wave velocity in the prediction of recurrence of atrial fibrillation among patients who
underwent successful direct current cardioversion for atrial fibrillation.

This will be a prospective cohort study designed to evaluate the value of atrial
electromechanical interval and pulse wave velocity in the prediction of recurrence of atrial
fibrillation among patients with atrial fibrillation with successful direct-current
cardioversion to sinus rhythm.

Should cardioversion be successful, a limited 2D echocardiogram will be done and the
following information will be measured: atrial electromechanical interval, left atrial
volume, left atrial size, ejection fraction, and maximal A-wave transmitral Doppler flow
velocity. The presence of left ventricular hypertrophy and valvular heart disease will be
recorded. In addition, baseline clinical information including age, gender, medications,
presence of HTN, DM, CAD, stroke, and prior history of atrial fibrillation will be obtained.

Radial artery applanation tonometry and pulse wave analysis will be used to calculate a
central aortic pressure and other parameters using commercially available SphygmoCor®
system. Central aortic pressures will be obtained immediately following measurement of
brachial artery pressures. Patients will be seated for 5 minutes in a quiet room after
which time blood pressure will be measured over the brachial artery three times at 5 minute
intervals. The mean of the last two measurements will be recorded as representative of the
brachial artery pressure. After the last measurement, radial artery pressure waveforms of
the same arm will be sampled over 10 seconds with a Millar tonometer and calibrated to the
average brachial pressure. Waveforms will be processed with dedicated software (SphygmoCor®
version 7, AtCor). The software will be used to calculate an averaged radial artery
waveform and to derive a corresponding central aortic pressure. Aortic pressure waveforms
will be subjected to further analysis by the SphygmoCor® software to identify the time to
the peak/shoulder of the first and second pressure wave components (T1, T2) during systole.
The pressure at the peak/shoulder of the first component sill be identified as P1 height
(outgoing pressure wave) and the pressure difference between P1 and the maximal pressure
during systole (∆P or augmentation) will be identified as the reflected pressure wave
occurring during systole. Augmentation index (AIx), defined as the ratio of augmentation to
central pulse pressure, will be expressed as the percentage: AIx = (∆P/PP) x 100, where P is
pressure and PP is pulse pressure. Pulse pressure amplification (PPA) will be expressed as
the ratio of central pulse pressure (CPP) to peripheral (brachial) pulse pressure (PPP): PPA
= PPP/CPP

Information will be recorded and the patients will be followed by their respective
cardiologists and evaluated for recurrence of atrial fibrillation within 6 months.

Primary endpoint for this study is clinical recurrence of atrial fibrillation or 6 month
time frame of sustained maintenance of sinus rhythm whichever comes first.

Inclusion Criteria:

- Age greater than or equal to 19 years of age

- History of atrial fibrillation with successful cardioversion to sinus rhythm

- Informed consent to participate in the study

Exclusion Criteria:

- Failure of cardioversion to sinus rhythm

- Use of anti-arrythmic drug therapy

- Refusal to participate in the study
We found this trial at
1
site
601 N 30th St
Omaha, Nebraska 68131
(402) 449-4000
Creighton University Medical Center St. Joseph's Mercy Hospital was founded on September 25, 1870 at...
?
mi
from
Omaha, NE
Click here to add this to my saved trials